Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:894938.
doi: 10.4061/2011/894938. Epub 2011 Jul 31.

MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues

Affiliations

MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues

Charlotte Delay et al. Int J Alzheimers Dis. 2011.

Abstract

Evidence from clinical trials as well as from studies performed in animal models suggest that both amyloid and tau pathologies function in concert with other factors to cause the severe neurodegeneration and dementia in Alzheimer's disease (AD) patients. Accumulating data in the literature suggest that microRNAs (miRNAs) could be such factors. These conserved, small nonprotein-coding RNAs are essential for neuronal function and survival and have been implicated in the regulation of key genes involved in genetic and sporadic AD. The study of miRNA changes in AD mouse models provides an appealing approach to address the cause-consequence relationship between miRNA dysfunction and AD pathology in humans. Mouse models also provide attractive tools to validate miRNA targets in vivo and provide unique platforms to study the role of specific miRNA-dependent gene pathways in disease. Finally, mouse models may be exploited for miRNA diagnostics in the fight against AD.

PubMed Disclaimer

References

    1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356. - PubMed
    1. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–185. - PubMed
    1. Golde TE, Schneider LS, Koo EH. Anti-Aβ therapeutics in alzheimer's disease: the need for a paradigm shift. Neuron. 2011;69(2):203–213. - PMC - PubMed
    1. Sambamurti K, Greig NH, Utsuki T, et al. Targets for AD treatment: conflicting messages from γ-secretase inhibitors. Journal of Neurochemistry. 2011;117(3):359–374. - PMC - PubMed
    1. Fan L-Y, Chiu M-J. Pharmacological treatment for Alzheimer's disease: current approaches and future strategies. Acta Neurologica Taiwanica. 2010;19(4):228–245. - PubMed

LinkOut - more resources